• Citer

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

par van der Burg, Maria;Griffin, Clare L;Guthrie, David;Lamont, Alan;Jayson, Gordon C;Kristensen, Gunnar;Mediola, César;Coens, Corneel;Qian, Wendi;Parmar, Mahesh K B;Swart, Anne Marie;MRC OV05, Pascal;EORTC 55955 investigators, ;Rustin,
Référence Lancet, 376, 9747, page (1155-1163)
Publication Publié, 2010-10

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Serum CA125 concentration often rises several months before clinical or symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 collaborative trial, we aimed to establish the benefits of early treatment on the basis of increased CA125 concentrations compared with delayed treatment on the basis of clinical recurrence.